Home › Therapeutic areas › Oncology › Prostate Cancer
Prostate Cancer (16 companies)
Companies with an active program in Prostate Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Programs |
|---|---|---|---|---|---|
| ADCT | ADC Therapeutics | Oncology | 1 | Approved | 5 |
| ACET | Adicet Bio | ImmunologyNeurology+2 Rare | 1 | Phase 1 | 8 |
| AKTS | Aktis Oncology | Oncology | 1 | Phase 1 | 10 |
| APVO | Aptevo Therapeutics | Oncology | 2 | Phase 1 | 8 |
| ARVN | Arvinas | NeurologyOncology Rare | 2 | Approved | 12 |
| BCTX | BriaCell Therapeutics | Oncology | 1 | Phase 3 | 7 |
| EIKN | Eikon Therapeutics | Oncology | 2 | Phase 2 | 13 |
| EXEL | Exelixis | CardiovascularOncology | 1 | Approved | 22 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 1 | Approved | 16 |
| INMB | Inmune Bio | DermatologyOncology Rare | 1 | Phase 2 | 2 |
| JANX | Janux Therapeutics | Oncology | 2 | Phase 1 | 3 |
| KAPA | Kairos Pharma | Oncology | 2 | Phase 2 | 9 |
| GLUE | Monte Rosa Therapeutics | CardiovascularDermatology+2 Rare | 1 | Phase 2 | 6 |
| VIR | Vir Biotechnology | Infectious DiseaseOncology Rare | 2 | Phase 3 | 10 |
| XNCR | Xencor | HematologyImmunology+4 Rare | 2 | Approved | 36 |
| ZYME | Zymeworks | OncologyRespiratory | 1 | Approved | 11 |
No companies match.